{
    "id": "0790",
    "question": "A 56-year-old patient is being treated with oral amoxicillin for community-acquired pneumonia. The plasma clearance of the drug is calculated as 15.0 L/h. Oral bioavailability of the drug is 75%. Sensitivity analysis of a sputum culture shows a minimal inhibitory concentration of 1 \u03bcg/mL for the causative pathogen. The target plasma concentration is 2 mg/L. If the drug is administered twice per day, which of the following dosages should be administered at each dosing interval to maintain a steady state?",
    "options": {
        "A": "270 mg",
        "B": "480 mg",
        "C": "240 mg",
        "D": "540 mg\n\""
    },
    "answer": "B",
    "predict": "To determine the dosage needed to maintain a steady state, we need to calculate the loading dose and then the maintenance dose. Given: - Oral bioavailability of amoxicillin = 75% - Plasma clearance of amoxicillin = 15.0 L/h - Target plasma concentration = 2 mg/L - Minimal inhibitory concentration (MIC) = 1 \u03bcg/mL = 0.001 mg/L - Dosing interval = twice per day (24 hours) First, calculate the loading dose: Loading dose = Target plasma concentration x Volume of distribution We need to calculate the volume of distribution (Vd) first: Vd = Clearance / (Bioavailability x Rate of elimination) Since we don't have the rate of elimination, we can use the formula: Rate of elimination = Clearance / (Target plasma concentration / MIC) Rate of elimination = 15.0 L/h / (2 mg/L / 0.001 mg/L) = 7,500 mg/h Vd = 15.0 L/h / (0.75 x 7,500 mg/h) = 0.4 L Now, calculate the loading dose: Loading dose = Target plasma concentration x Vd = 2 mg/L x 0.4 L = 0.8 mg However, since the dose should be given in milligrams, we need to convert it to milligrams: Loading dose = 0.8 mg x 1000 mg/g = 800 mg Since the loading dose is given at the first dose, the remaining doses will be maintenance doses. To maintain a steady state, the total dose administered per day should equal the loading dose divided by the dosing interval: Maintenance dose per dose = Loading dose / Dosing interval = 800 mg / 24 h = 33.33 mg/h Since the dosing interval is 12 hours (twice per day), we need to calculate the maintenance dose for each dose: Maintenance dose per dose = 33.33 mg/h x 2 = 66.67 mg However, this is not among the answer options. We need to find the closest option. The closest option is 66.67 mg is not available, but 60 mg and 72 mg are available. We can see that 72 mg is greater than 66.67 mg, and the difference between 72 mg and 66.67 mg is 5.33 mg, which is less than 10 mg. Since the dosing interval is 12 hours, we can assume that the patient will tolerate a dose of 72 mg. Therefore, the answer is: {\"step_by_step_thinking\": \"To calculate the dosage needed to maintain a steady state, we first need to calculate the loading dose and then the maintenance dose. Given the oral bioavailability of amoxicillin, plasma clearance, target plasma concentration, and minimal inhibitory concentration, we can calculate the volume of distribution and then the loading dose. Since the dosing interval is 24 hours, we need to divide the loading dose by 2 to get the maintenance dose. The closest available option to the calculated maintenance dose of 66.67 mg is 72 mg.\", \"answer_choice\": \"D\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_4982",
            "title": "Pharmacology_Katzung",
            "content": "A. Oral Cefuroxime axetil is the most commonly used oral cephalosporin in the USA. The usual dosage for adults is 250\u2013500 mg orally twice daily; children should be given 20\u201340 mg/kg/d up to a maximum of 1 g/d. These drugs are not predictably active against penicillin-non-susceptible pneumococci. B. Parenteral After a 1-g intravenous infusion, serum levels are 75\u2013125 mcg/mL for most second-generation cephalosporins. Intramuscular administration is painful and should be avoided. Doses and dosing intervals vary depending on the specific agent (Table 43\u20132). There are differences in half-life, protein binding, and interval between doses. All are renally cleared and require dosage adjustment in renal failure."
        },
        {
            "id": "InternalMed_Harrison_13642",
            "title": "InternalMed_Harrison",
            "content": "Injectable Agents \u2022 caPreoMycin Capreomycin, a cyclic peptide antibiotic derived from Streptomyces capreolus, is an important first-choice second-line agent used for treatment of MDR-TB, particularly when additional resistance to aminoglycosides is documented. Capreomycin is administered by the IM route; an inhaled preparation is under study. A dose of 15 mg/kg per day is given five to seven times per week (maximal daily dose, 1 g) and results in peak blood levels of 20\u201340 \u03bcg/mL. The dosage may be reduced to 1 g two or three times per week 2\u20134 months after mycobacterial cultures become negative. For individuals \u226560 years of age, the dose should be reduced to 10 mg/kg per day (maximal daily dose, 750 mg). For patients with renal insufficiency, the drug should be given intermittently and at lower dosage (12\u201315 mg/kg two or three times per week). A minimal duration of 3 months is recommended for MDR-TB treatment. Penetration of capreomycin into the CSF is believed to be poor."
        },
        {
            "id": "Pharmacology_Katzung_4967",
            "title": "Pharmacology_Katzung",
            "content": "The aminopenicillins, ampicillin and amoxicillin, have very similar spectrums of activity, but amoxicillin is better absorbed orally. Amoxicillin, 250\u2013500 mg three times daily, is equivalent to the same amount of ampicillin given four times daily. Amoxicillin is given orally to treat bacterial sinusitis, otitis, and lower respiratory tract infections. Ampicillin and amoxicillin are the most active of the oral \u03b2-lactam antibiotics against pneumococci with elevated MICs to penicillin and are the preferred \u03b2-lactam antibiotics for treating infections suspected to be caused by these strains. Ampicillin (but not amoxicillin) is effective for shigellosis. Ampicillin, at dosages of 4\u201312 g/d intravenously, is useful for treating serious infections caused by susceptible organisms, including anaerobes, enterococci, L monocytogenes, and \u03b2-lactamase-negative strains of Gram-negative cocci and bacilli such as E coli, and Salmonella sp. Non-\u03b2-lactamase-producing strains of H influenzae are"
        },
        {
            "id": "InternalMed_Harrison_10467",
            "title": "InternalMed_Harrison",
            "content": "Individualized oral regimens chosen in light of antimicrobial susceptibility aAntimicrobial agents should be chosen in light of the isolate\u2019s in vitro susceptibility, the patient\u2019s drug allergies and intolerances, potential drug interactions, and contraindications to specific drugs. All dosages recommended are for adults with normal renal and hepatic function. See text for total durations of antibiotic treatment. bOther dosages and intervals of administration with equivalent success rates have been reported. cWhen the patient has delayed-type penicillin hypersensitivity, cefazolin (2 g IV q8h) can be administered. When the patient has immediate-type penicillin hypersensitivity, the penicillin should be replaced by vancomycin (1 g IV q12h). dTrimethoprim-sulfamethoxazole. A double-strength tablet contains 160 mg of trimethoprim and 800 mg of sulfamethoxazole. eDetermination of the minimal inhibitory concentration (MIC) of penicillin is advisable. fCombination therapy with an"
        },
        {
            "id": "Pharmacology_Katzung_4962",
            "title": "Pharmacology_Katzung",
            "content": "A. Penicillin Penicillin G is a drug of choice for infections caused by streptococci, meningococci, some enterococci, penicillin-susceptible pneumococci, staphylococci confirmed to be non-\u03b2-lactamaseproducing, Treponema pallidum and certain other spirochetes, some Clostridium species, Actinomyces and certain other Gram-positive rods, and non-\u03b2-lactamase-producing Gram-negative anaerobic organisms. Depending on the organism, the site, and the severity of infection, effective doses range between 4 and 24 million units per day administered intravenously in four to six divided doses. High-dose penicillin G can also be given as a continuous intravenous infusion. Penicillin V, the oral form of penicillin, is indicated only in minor infections because of its relatively poor bioavailability, the need for dosing four times a day, and its narrow antibacterial spectrum. Amoxicillin (see below) is often used instead."
        },
        {
            "id": "Pharmacology_Katzung_5147",
            "title": "Pharmacology_Katzung",
            "content": "A. Intramuscular or Intravenous Administration Gentamicin is used mainly in severe infections caused by Gram-negative bacteria that are likely to be resistant to other drugs, especially P aeruginosa, Enterobacter sp, Serratia marcescens, Proteus sp, Acinetobacter sp, and Klebsiella sp. It usually is used in combination with a second agent because an aminoglycoside alone may not be effective for infections outside the urinary tract. Aminoglycosides should not be used as single agents for therapy of pneumonia because penetration of infected lung tissue is poor and local conditions of low pH and low oxygen tension contribute to limited activity. Gentamicin 5\u20137 mg/kg/d traditionally is given intravenously in three equal doses, but once-daily administration is just as effective for some organisms and less toxic (see above)."
        },
        {
            "id": "InternalMed_Harrison_11649",
            "title": "InternalMed_Harrison",
            "content": "For outpatient management, amoxicillin (1 g every 8 h) provides effective treatment for virtually all cases of pneumococcal pneumonia. Neither cephalosporins nor quinolones, which are far more expensive, offer any advantage over amoxicillin. Levofloxacin (500\u2013750 mg/d as a single dose) and moxifloxacin (400 mg/d as a single dose) also are highly likely to be effective in the United States except in patients who come from closed populations where these drugs are used widely or who have themselves been treated recently with a quinolone. Clindamycin (600\u20131200 mg/d every 6 h) is effective in 90% of cases and azithromycin (500 mg on day 1 followed by 250\u2013500 mg/d) or clarithromycin (500\u2013750 mg/d as a single dose) in 80% of cases. Treatment failure resulting in bacteremic disease due to macrolide-resistant isolates has been amply documented in patients given azithromycin empirically. As noted above, rates of resistance to all these antibiotics are relatively low in some countries and much"
        },
        {
            "id": "InternalMed_Harrison_12631",
            "title": "InternalMed_Harrison",
            "content": "(Table 189-2) Therapy for P. aeruginosa pneumonia has been unsatisfactory. Reports suggest mortality rates of 40\u201380%, but how many of these deaths are attributable to underlying disease remains unknown. The drugs of choice for P. aeruginosa pneumonia are similar to those given for bacteremia. A potent antipseudomonal \u03b2-lactam drug is the mainstay of therapy. Failure rates were high when aminoglycosides were used as single agents, possibly because of their poor penetration into the airways and their binding to airway secretions. Thus a strong case cannot be made for the inclusion of the aminoglycoside component in regimens used against fully susceptible organisms, especially given the evidence that aminoglycosides are not optimally active in the lungs at concentrations normally reached after IV administration. Nonetheless, aminoglycosides are commonly used in clinical practice. Some experts suggest the combination of a \u03b2-lactam agent and an antipseudomonal fluoroquinolone instead when"
        },
        {
            "id": "InternalMed_Harrison_2583",
            "title": "InternalMed_Harrison",
            "content": "An antipneumococcal fluoroquinolone (e.g., moxifloxacin, 400 mg PO daily) Recent treatment failure: Amoxicillin/clavulanate (extended release), 2000 mg PO bid; or An antipneumococcal fluoroquinolone (e.g., moxifloxacin, 400 mg PO daily) aThe duration of therapy is generally 7\u201310 days (with consideration of a 5-day course), with appropriate follow-up. Severe disease may warrant IV antibiotics and consideration of hospital admission. bAlthough the evidence is not as strong, amoxicillin/clavulanate may be considered for initial use, particularly if local rates of penicillin resistance or \u03b2-lactamase production are high."
        },
        {
            "id": "Pharmacology_Katzung_4954",
            "title": "Pharmacology_Katzung",
            "content": "Absorption of orally administered drug differs greatly for individual penicillins, depending in part on their acid stability and protein binding. Gastrointestinal absorption of nafcillin is erratic, so it is not suitable for oral administration. Dicloxacillin, ampicillin, and amoxicillin are acid-stable and relatively well absorbed, producing serum concentrations in the range of 4\u20138 mcg/mL after a 500-mg oral dose. Absorption of most oral penicillins (amoxicillin being an exception) is impaired by food, and the drugs should be administered at least 1\u20132 hours before or after a meal."
        },
        {
            "id": "InternalMed_Harrison_14016",
            "title": "InternalMed_Harrison",
            "content": "Although in the majority of untreated cases symptoms resolve within 2\u20133 weeks without significant associated morbidity, M. pneumoniae pneumonia can be a serious illness that responds to appropriate antimicrobial therapy (Table 212-2). Randomized, double-blind, placebo-controlled trials in adults have demonstrated that antimicrobial treatment significantly decreases the duration of fever, cough, malaise, hospitalization, and radiologic abnormalities in M. pneumoniae pneumonia. Treatment options for acute M. pneumoniae infection include macrolides (e.g., oral azithromycin, 500 mg on day 1, then 250 mg/d on days 2\u20135), tetracyclines (e.g., oral doxycycline, 100 mg twice daily for 10\u201314 days), and respiratory fluoroquinolones. However, ciprofloxacin and ofloxacin are not recommended because of their high minimal inhibitory concentrations against M. pneumoniae isolates and their poor performance in experimental studies. A 10to 14-day course of quinolone therapy appears adequate."
        },
        {
            "id": "Pharmacology_Katzung_5659",
            "title": "Pharmacology_Katzung",
            "content": "Mandell LA et al: Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27. because of underlying disease (eg, immunocompromised hosts). Prophylaxis is most effective when directed against organisms that are predictably susceptible to antimicrobial agents. Common indications and drugs for nonsurgical prophylaxis are listed in Table 51\u20138."
        },
        {
            "id": "Pharmacology_Katzung_337",
            "title": "Pharmacology_Katzung",
            "content": "A target plasma theophylline concentration of 10 mg/L is desired to relieve acute bronchial asthma in a patient. If the patient is a nonsmoker and otherwise normal except for asthma, we may use the mean clearance given in Table 3\u20131, ie, 2.8 L/h/70 kg. Since the drug will be given as an intravenous infusion, F = 1. Dosing rate = CL \u00d7 TC = 2.8 L/h/70 kg \u00d7 10 mg/L = 28 mg/h/70 kg Therefore, in this patient, the infusion rate would be 28 mg/h/ 70 kg. If the asthma attack is relieved, the clinician might want to maintain this plasma level using oral theophylline, which might be given every 12 hours using an extended-release formulation to approximate a continuous intravenous infusion. According to Table 3\u20131, Foral is 0.96. When the dosing interval is 12 hours, the size of each maintenance dose would be: Maintenance dose = Dosing Rate/F \u00d7 Dosing interval = 28 mg/h/0.96 \u00d7 12 h = 350 mg A tablet or capsule size close to the ideal dose of 350 mg would then be prescribed at 12-hour intervals."
        },
        {
            "id": "Pharmacology_Katzung_339",
            "title": "Pharmacology_Katzung",
            "content": "CHAPTER 3 Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action FIGURE 3\u20136 Relationship between frequency of dosing and maximum and minimum plasma concentrations when a steady-state theophylline plasma level of 10 mg/L is desired. The smoothly rising black line shows the plasma concentration achieved with an intravenous infusion of 28 mg/h. The doses for 8-hour administration (orange line) are 224 mg; for 24-hour administration (blue line), 672 mg. In each of the three cases, the mean steady-state plasma concentration is 10 mg/L. For the theophylline example given in the box, Example: Maintenance Dose Calculations, the loading dose would be 350 mg (35 L \u00d7 10 mg/L) for a 70-kg person. For most drugs, the loading dose can be given as a single dose by the chosen route of administration."
        },
        {
            "id": "Pharmacology_Katzung_5107",
            "title": "Pharmacology_Katzung",
            "content": "Linezolid is 100% bioavailable after oral administration and has a half-life of 4\u20136 hours. It is metabolized by oxidative metabolism, yielding two inactive metabolites. It is neither an inducer nor an inhibitor of cytochrome P450 enzymes. Peak serum concentrations average 18 mcg/mL following a 600-mg oral dose; cerebrospinal fluid (CSF) concentrations reach approximately 60\u201370% of the serum level. The recommended dosage for most indications is 600 mg twice daily, either orally or intravenously. Linezolid is approved for vancomycin-resistant E faecium infections, health care\u2013associated pneumonia, community-acquired pneumonia, and both complicated and uncomplicated skin and soft tissue infections caused by susceptible Gram-positive bacteria. Off-label uses of linezolid include treatment of multidrugresistant tuberculosis and Nocardia infections."
        },
        {
            "id": "Pharmacology_Katzung_333",
            "title": "Pharmacology_Katzung",
            "content": "In most clinical situations, drugs are administered in such a way as to maintain a steady state of drug in the body, ie, just enough drug is given in each dose to replace the drug eliminated since the preceding dose. Thus, calculation of the appropriate maintenance dose is a primary goal. Clearance is the most important pharmacokinetic term to be considered in defining a rational steady-state drug dosage regimen. At steady state, the dosing rate (\u201crate in\u201d) must equal the rate of elimination (\u201crate out\u201d). Substitution of the target concentration (TC) for concentration (C) in equation (4) predicts the maintenance dosing rate: Thus, if the desired target concentration is known, the clearance in that patient will determine the dosing rate. If the drug is given by a route that has a bioavailability less than 100%, then the dosing rate predicted by equation (9) must be modified. For oral dosing:"
        },
        {
            "id": "InternalMed_Harrison_9508",
            "title": "InternalMed_Harrison",
            "content": "Community-S. pneumoniae, acquired, Mycoplasma pneuoutpatient moniae, Haemophilus influenzae, Chlamydia pneumoniae Inpatient, non-ICU Above plus Legionella spp. Inpatient, ICU Above plus S. aureus Hospital-acquired S. pneumoniae, pneumoniad H. influenzae, S. aureus, gram-negative bacilli (e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter spp.) Mild to moderate Anaerobes (Bacteroides severity spp., Clostridium spp.), gram-negative bacilli (Escherichia coli), Streptococcus spp. High-risk patient Same as above or high degree of severity Vancomycin, 15 mg/kg q12hb; A broad-spectrum antipseudomonal \u03b2-lactam (piperacillin-tazobactam, 4.5 g q6h; imipenem, 1 g q8h; meropenem, 1 g q8h; or cefepime, 1\u20132 g q8\u201312h) Vancomycin, 15 mg/kg q12hb; Ceftriaxone, 2 g q12h Vancomycin, 15 mg/kg q12hb; Ceftriaxone, 2 g q12h; Metronidazole, 500 mg q8h Vancomycin, 15 mg/kg q12hb; Ceftriaxone, 2 g q12h Azithromycin, 500 mg PO \u00d7 1, then 250 mg PO qd \u00d7 4 days"
        },
        {
            "id": "Pharmacology_Katzung_334",
            "title": "Pharmacology_Katzung",
            "content": "If intermittent doses are given, the maintenance dose is calculated from: (See Box: Example: Maintenance Dose Calculations.) Note that the steady-state concentration achieved by continuous infusion or the average concentration following intermittent dosing depends only on clearance. The volume of distribution and the half-life need not be known in order to determine the average plasma concentration expected from a given dosing rate or to predict the dosing rate for a desired target concentration. Figure 3\u20136 shows that at different dosing intervals, the concentration-time curves will have different maximum and minimum values even though the average concentration will always be 10 mg/L."
        },
        {
            "id": "InternalMed_Harrison_10140",
            "title": "InternalMed_Harrison",
            "content": "The minimal inhibitory concentration (MIC) cutoffs for penicillin in pneumonia are \u22642 \u03bcg/mL for susceptibility, >2\u20134 \u03bcg/mL for intermediate, and \u22658 \u03bcg/mL for resistant. A change in susceptibility thresholds resulted in a dramatic decrease in the proportion of pneumococcal isolates considered nonsusceptible. For meningitis, MIC thresholds remain at the former higher levels. Fortunately, resistance to penicillin appeared to plateau even before the change in MIC thresholds. Pneumococcal resistance to \u03b2-lactam drugs is due solely to low-affinity penicillin-binding proteins. Risk factors for penicillin-resistant pneumococcal infection include recent antimicrobial therapy, an age of <2 years or >65 years, attendance at day-care centers, recent hospitalization, and HIV infection."
        },
        {
            "id": "InternalMed_Harrison_10148",
            "title": "InternalMed_Harrison",
            "content": "Therapy with a macrolide or a fluoroquinolone within the previous 3 months is associated with an increased likelihood of infection with a resistant strain of S. pneumoniae. For this reason, a fluoroquinolone-based regimen should be used for patients recently given a macrolide, and vice versa (Table 153-5). 1. Previously healthy and no antibiotics in past 3 months PO once, then 250 mg qd]) or 2. Comorbidities or antibiotics in past 3 months: select an alternative from a different class \u2022 A respiratory fluoroquinolone (moxifloxacin [400 mg PO qd], gemifloxacin [320 mg PO qd], levofloxacin [750 mg PO qd]) or \u2022 A \u03b2-lactam (preferred: high-dose amoxicillin [1 g tid] or amoxicillin/ clavulanate [2 g bid]; alternatives: ceftriaxone [1\u20132 g IV qd], cefpodoxime [200 mg PO bid], cefuroxime [500 mg PO bid]) plus a macrolidea 3. In regions with a high rate of \u201chigh-level\u201d pneumococcal macrolide resistance,b consider alternatives listed above for patients with comorbidities."
        },
        {
            "id": "Pharmacology_Katzung_5624",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 51\u20132 Empiric antimicrobial therapy based on site of infection. Child H influenzae, pneumococcus, Ceftriaxone or cefotaxime \u00b1 Chloramphenicol, meropenem meningococcus vancomycin3 1See footnote 9, Table 51\u20131. 2See footnote 2, Table 51\u20131. 3When meningitis with penicillin-resistant pneumococcus is suspected, empiric therapy with this regimen is recommended. 4Erythromycin, clarithromycin, or azithromycin (an azalide) may be used. 5Quinolones used to treat pneumonococcal infections include levofloxacin, moxifloxacin, and gemifloxacin. 6Adjunctive immunomodulatory drugs such as drotrecogin-alfa can also be considered for patients with severe sepsis. determine the cause of failure. Errors in susceptibility testing are rare, but the original results should be confirmed by repeat testing. Drug dosing and absorption should be scrutinized and tested directly using serum measurements, pill counting, or directly observed therapy."
        },
        {
            "id": "InternalMed_Harrison_11495",
            "title": "InternalMed_Harrison",
            "content": "For concentration-dependent killing agents, as the designation implies, the higher the drug concentration, the higher the rate and extent of bacterial killing. Aminoglycosides fit into the Cmax/MIC model of pharmacodynamics activity, and a particular peak serum concentration is often targeted to achieve optimal killing. Fluoroquinolones exemplify antibacterial agents for which the AUC/MIC is a predictor of efficacy. For example, studies have found that an AUC/MIC ratio of >30 will maximize killing of S. pneumoniae by fluoroquinolones. In contrast, time-dependent killing agents reach a ceiling at which higher concentrations do not result in increased effect. Instead, these agents are active against bacteria only when the drug concentration is above the MIC. The T>MIC predicts clinical efficacy for all \u03b2-lactams. The longer the concentration of the \u03b2-lactam remains above the MIC for an infecting pathogen during the dosing interval, the greater the killing effect. For some drug classes,"
        },
        {
            "id": "Pharmacology_Katzung_5085",
            "title": "Pharmacology_Katzung",
            "content": "Azithromycin differs from erythromycin and clarithromycin mainly in pharmacokinetic properties. A 500-mg dose of azithromycin produces relatively low serum concentrations of approximately 0.4 mcg/mL. However, azithromycin penetrates into most tissues (except cerebrospinal fluid) and phagocytic cells extremely well, with tissue concentrations exceeding serum concentrations by 10to 100-fold. The drug is slowly released from tissues (tissue half-life of 2\u20134 days) to produce an elimination half-life approaching 3 days. These unique properties permit once-daily dosing and shortening of the duration of treatment in many cases. For example, a single 1-g dose of azithromycin is as effective as a 7-day course of doxycycline for chlamydial cervicitis and urethritis. Azithromycin, as a 500-mg loading dose, followed by a 250-mg single daily dose for the next 4 days, is commonly used alone or in combination with a beta-lactam antibiotic to treat community-acquired pneumonia."
        },
        {
            "id": "InternalMed_Harrison_11753",
            "title": "InternalMed_Harrison",
            "content": "Resistant to methicillin Clindamycin (300\u2013450 mg/kg tid), Same options as under \u201cDrug of It is important to know the antibiotic susceptibility of TMP-SMX (1 or 2 ds tablets bid), mino-Choice\u201d isolates in the specific geographic region. All draincycline or doxycycline (100 mg q12hb), age should be cultured. linezolid (600 mg bid) or tedizolid (200 mg once daily) aRecommended dosages are for adults with normal renal and hepatic function. bThe dosage must be adjusted for patients with reduced creatinine clearance. cFor the treatment of prosthetic-valve endocarditis, the addition of gentamicin (1 mg/kg q8h) and rifampin (300 mg PO q8h) is recommended, with adjustment of the gentamicin dosage if the creatinine clearance rate is reduced. dDaptomycin cannot be used for the treatment of pneumonia. eVancomycin-resistant S. aureus isolates from clinical infections have been reported."
        },
        {
            "id": "InternalMed_Harrison_10189",
            "title": "InternalMed_Harrison",
            "content": "Recommended options for empirical therapy are listed in Table 153-9. Treatment should be started once diagnostic specimens have been obtained. The major factor in the selection of agents is the presence of risk factors for MDR pathogens. Choices among the various options listed depend on local patterns of resistance and\u2014a very important factor\u2014the patient\u2019s prior antibiotic exposure. The majority of patients without risk factors for MDR infection can be treated with a single agent. The major difference from CAP is the markedly lower incidence of atypical pathogens in VAP; the exception is Legionella, which can be a nosocomial pathogen, especially with breakdowns in the treatment of potable water in the hospital. Moxifloxacin (400 mg IV q24h), ciprofloxacin (400 mg IV q8h), or levofloxacin (750 mg IV q24h) or Ampicillin/sulbactam (3 g IV q6h) or Ertapenem (1 g IV q24h) Patients with Risk Factors for MDR Pathogens 1. A \u03b2-lactam: Piperacillin/tazobactam (4. 5 g IV q6h) or"
        },
        {
            "id": "InternalMed_Harrison_16267",
            "title": "InternalMed_Harrison",
            "content": "Chloroquine is well absorbed. However, because it exhibits extensive tissue binding, a loading dose is required to yield effective plasma concentrations. A therapeutic drug level in plasma is reached 2\u20133 h after oral administration (the preferred route). Chloroquine can be administered IV, but excessively rapid parenteral administration can result in seizures and death from cardiovascular collapse. The mean half-life of chloroquine is 4 days, but the rate of excretion decreases as plasma levels decline, making once-weekly administration possible for prophylaxis in areas with sensitive strains. About one-half of the parent drug is excreted in urine, but the dose should not be reduced for persons with acute malaria and renal insufficiency. Ciprofloxacin See Table 246e-1 and Chap. 170. Clindamycin See Table 246e-1 and Chap. 170. Dapsone See Table 246e-1 and Chap. 205e."
        },
        {
            "id": "InternalMed_Harrison_13623",
            "title": "InternalMed_Harrison",
            "content": "M. tuberculosis. Susceptible strains of M. tuberculosis are inhibited by pyrazinamide concentrations of 16\u201350 \u03bcg/mL at pH 5.5. PharMacology anD Dosing Pyrazinamide is well absorbed after oral administration, with peak serum concentrations of 20\u201360 \u03bcg/mL at 1\u20132 h after ingestion of the recommended adult daily dose of 15\u201330 mg/kg (maximum, 2 g/d). It distributes well to various body compartments, including CSF, and is an important component of treatment for tuberculous meningitis. The serum half-life of the drug is 9\u201311 h with normal renal and hepatic function. Pyrazinamide is metabolized in the liver to POA, 5-hydroxypyrazinamide, and 5-hydroxy-POA. A high proportion of pyrazinamide and its metabolites (~70%) is excreted in the urine. The dosage must be adjusted according to the level of renal function in patients with reduced creatinine clearance."
        },
        {
            "id": "InternalMed_Harrison_10149",
            "title": "InternalMed_Harrison",
            "content": "Inpatients, Non-ICU \u2022 A respiratory fluoroquinolone (e.g., moxifloxacin [400 mg PO or IV qd] or \u2022 A \u03b2-lactamc (e.g., ceftriaxone [1\u20132 g IV qd], ampicillin [1\u20132 g IV q4\u20136h], cefotaxime [1\u20132 g IV q8h], ertapenem [1 g IV qd]) plus a macrolided (e.g., oral clarithromycin or azithromycin [as listed above] or IV azithromycin [1 g once, then 500 mg qd]) Inpatients, ICU \u2022 A \u03b2-lactame (e.g., ceftriaxone [2 g IV qd], ampicillin-sulbactam [2 g IV q8h], or cefotaxime [1\u20132 g IV q8h]) plus either azithromycin or a fluoroquinolone (as listed above for inpatients, non-ICU) If Pseudomonas is a consideration: \u2022 An antipseudomonal \u03b2-lactam (e.g., piperacillin/tazobactam [4. 5 g IV q6h], cefepime [1\u20132 g IV q12h], imipenem [500 mg IV q6h], meropenem [1 g IV q8h]) plus either ciprofloxacin (400 mg IV q12h) or levofloxacin (750 mg IV qd) \u2022 The above \u03b2-lactams plus an aminoglycoside (amikacin [15 mg/kg qd] or tobramycin [1. 7 mg/kg qd]) plus azithromycin \u2022 The"
        },
        {
            "id": "InternalMed_Harrison_12205",
            "title": "InternalMed_Harrison",
            "content": "Third-generation cephalosporins have remained highly effective as single-dose therapy for gonorrhea, but the recent isolation of strains highly resistant to ceftriaxone (minimal inhibitory concentrations [MICs], 2 \u03bcg/mL) in Japan and some European countries is cause for concern. Even though the MICs of ceftriaxone against certain strains may reach 0.015\u20130.125 \u03bcg/mL (higher than the MICs of 0.0001\u20130.008 \u03bcg/mL for fully susceptible strains), these levels are greatly exceeded in the blood, the urethra, and the cervix when the routinely recommended parenteral dose of ceftriaxone is administered. The rising MICs of oral cefixime (the previously recommended alternative oral third-generation cephalosporin) against N. gonorrhoeae, combined with this drug\u2019s limited capacity to reach levels sufficiently higher than MICs in the blood, the urethra, the cervix, and especially the pharynx, have resulted in the removal of cefixime from the list of first-line agents for treatment of uncomplicated"
        },
        {
            "id": "InternalMed_Harrison_13603",
            "title": "InternalMed_Harrison",
            "content": "The minimal inhibitory concentrations (MICs) of isoniazid for wild-type (untreated) susceptible strains are <0.1 \u03bcg/mL for M. tuberculosis and 0.5\u20132 \u03bcg/mL for Mycobacterium kansasii. PharMacology Isoniazid is the hydrazide of isonicotinic acid, a small, water-soluble molecule. The usual adult oral daily dose of 300 mg results in peak serum levels of 3\u20135 \u03bcg/mL within 30 min to 2 h after ingestion\u2014well in excess of the MICs for most susceptible strains of M. tuberculosis. Both oral and IM preparations of isoniazid reach effective levels in the body, although antacids and high-carbohydrate meals may interfere with oral absorption. Isoniazid diffuses well throughout the body, reaching therapeutic concentrations in body cavities and fluids, with concentrations in cerebrospinal fluid (CSF) comparable to those in serum."
        },
        {
            "id": "Pharmacology_Katzung_5213",
            "title": "Pharmacology_Katzung",
            "content": "Mandell LA et al: Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007;44:S27. Mwenya DM et al: Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 2010;54:3756. Nouira S et al: Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: A randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis 2010;51:143. Rodriguez-Martinez JM et al: Plasmid-mediated quinolone resistance: An update. J Infect Chemother 2011;17:149. Scheld WM: Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003;9:1."
        },
        {
            "id": "InternalMed_Harrison_10294",
            "title": "InternalMed_Harrison",
            "content": "otHer organisms In the absence of meningitis, endocarditis caused by Streptococcus pneumoniae isolates with a penicillin MIC of \u22641 \u03bcg/mL can be treated with IV penicillin (4 million units every 4 h), ceftriaxone (2 g/d as a single dose), or cefotaxime (at a comparable dosage). Infection caused by pneumococcal strains with a penicillin MIC of \u22652 \u03bcg/mL should be treated with vancomycin. If meningitis is suspected or present, treatment with vancomycin plus ceftriaxone\u2014at the doses advised for meningitis\u2014should be initiated until susceptibility results are known. Definitive therapy should then be selected on the basis of meningitis breakpoints (penicillin MIC, 0.06 \u03bcg/mL; or ceftriaxone MIC, 0.5 \u03bcg/mL). P. aeruginosa endocarditis is treated with an antipseudomonal penicillin (ticarcillin or piperacillin) and high doses of tobramycin (8 mg/kg per day in three divided doses). Endocarditis caused by Enterobacteriaceae is treated with a potent \u03b2-lactam antibiotic plus an aminoglycoside."
        }
    ],
    "scores": [
        0.027255782929289055,
        0.024356345408976986,
        0.02236057296027311,
        0.02223344151941339,
        0.021191606430035603,
        0.020763031323180508,
        0.019801980198019802,
        0.01886960391633289,
        0.0186932215234102,
        0.01835016835016835,
        0.018268268268268266,
        0.017949553586015014,
        0.01752123786407767,
        0.017370470200658877,
        0.01709901351845086,
        0.016998166172943998,
        0.01692155196828094,
        0.016498316498316498,
        0.016280566280566282,
        0.016036949130797357,
        0.01575757575757576,
        0.015675990675990677,
        0.01566111881645862,
        0.015549662487945998,
        0.015407319952774497,
        0.015159345391903532,
        0.015142857142857142,
        0.014989517819706498,
        0.014815627743634766,
        0.014668817421111001,
        0.014668817421111001,
        0.01439173603450005
    ]
}